11d
U.S. FDA Grants RMAT Designation to GS-100, Grace Science’s Gene Therapy to Treat NGLY1 Deficiency
Grace Science, LLC, a biotechnology company founded to develop novel therapies based on the function of NGLY1, announced ...
MENLO PARK, Calif.--(BUSINESS WIRE)--Grace Science, LLC announced today that the first patient was dosed in an open-label Phase 1/2/3 clinical trial of GS-100, an AAV9 gene replacement therapy for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results